Suppr超能文献

放射治疗联合多西他赛和奥沙利铂化疗对局部晚期鼻咽癌患者有效。

Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma.

作者信息

Pan Feng, Ruan Zhihua, Li Jianjun, Pang Xueli, Zhang Yanling, Zou Lan, Liang Houjie

机构信息

Department of Oncology, Southwest Cancer Center, Southwest Hospital, Third Military Medical University, 29 Gaotanyan Main Street, Shapingba District, Chongqing, 400038, China.

出版信息

Med Oncol. 2015 Nov;32(11):252. doi: 10.1007/s12032-015-0698-4. Epub 2015 Oct 15.

Abstract

The outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unsatisfactory due to high rates of local and distant failure, and the best way of integration of chemotherapy to chemoradiotherapy was still undefined. The aim of this study was to evaluate the efficacy of radiotherapy combined docetaxel and oxaliplatin (TP) chemotherapy in patients with locally advanced NPC. A total of 62 patients in stages III-IVA with a newly diagnosed and previously untreated NPC were enrolled in this study. All patients received 70-74 Gy in 7 weeks using standard intensity-modulated radiotherapy (IMRT) portals and techniques. A combination of TP chemotherapy were used every 3 weeks for two cycles before and after IMRT. Response analysis including toxicities, efficacy and survival were made 3 months after termination of radiotherapy. No grade 5 toxicity (death) occurred during treatment, and the most common grade 3 hematologic toxicities during chemotherapy were neutropenia (37.1 %), thrombocytopenia (4.8 %) and anemia (4.8 %). The progression free survival rate of 1- , 3- and 5-year were 96.8, 75.8 and 64.5 %, respectively. The overall survival rate of 1- , 3- and 5-year were 100, 82.3 and 75.8 %, respectively. Our findings suggest that induction chemotherapy of TP to IMRT may provide potential improvement of tumor control probability for advanced NPC.

摘要

由于局部和远处转移的高发生率,局部晚期鼻咽癌(NPC)的治疗结果仍不尽人意,化疗与放化疗联合的最佳方式仍未明确。本研究旨在评估多西他赛和奥沙利铂(TP)化疗联合放疗对局部晚期鼻咽癌患者的疗效。本研究共纳入62例新诊断且未经治疗的III-IVA期鼻咽癌患者。所有患者均采用标准调强放疗(IMRT)射野和技术,在7周内接受70-74 Gy的放疗。在IMRT前后每3周进行一次TP化疗联合,共两个周期。放疗结束3个月后进行包括毒性、疗效和生存情况的反应分析。治疗期间未发生5级毒性反应(死亡),化疗期间最常见的3级血液学毒性为中性粒细胞减少(37.1%)、血小板减少(4.8%)和贫血(4.8%)。1年、3年和5年无进展生存率分别为96.8%、75.8%和64.5%。1年、3年和5年总生存率分别为100%、82.3%和75.8%。我们的研究结果表明,对IMRT进行TP诱导化疗可能会提高晚期鼻咽癌的肿瘤控制概率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验